Interview: Dr. Tas Discusses Innovative Approaches in the Treatment of Peyronie’s Disease

Presenter: Today, we have the pleasure of talking to Dr. Tas about the latest advancements in the treatment of Peyronie’s disease in 2024. Welcome, Dr. Tas.

Dr. Tas: Thank you, it’s a pleasure to be here.

Presenter: To start, can you provide an overview of Peyronie’s disease and its prevalence?

Dr. Tas: Peyronie’s disease, first described in 1793 by Francois G. de la Peyronie, involves the formation of fibrous scar tissue beneath the skin of the penis. This results in palpable hardness, shortening, curvature, painful erection, and decreased erectile function. It’s crucial to note that Peyronie’s disease is not cancer-related. The prevalence varies widely in studies, ranging from 0.38% to 23%, with an estimated global occurrence of 0.3% to 13.1%, potentially higher in individuals with associated risk factors.

Presenter: Let’s delve into treatment methods, starting with Extracorporeal Shock Wave Therapy (ESWT). How does ESWT assist in Peyronie’s disease?

Dr. Tas: While the exact mechanism isn’t fully understood, ESWT is a non-invasive approach aimed at plaque regulation through mechanical damage and potential regression by increasing nitric oxide and VEGF in the tissue.

Presenter: What do studies reveal about ESWT?

Dr. Tas: Some studies show significant improvements in pain scores and plaque size, but overall, it’s not consistently effective. Current guidelines do not recommend ESWT for Peyronie’s treatment.

Presenter: Understood. Now, let’s talk about Cellular therapy. How does it contribute to Peyronie’s treatment?

Dr. Tas: Cellular therapy, with their tissue repair and anti-inflammatory properties, show promise in Peyronie’s treatment. Adipose tissue-derived Cellular therapy, easily obtainable, have demonstrated a reduction in plaque size and curvature improvement in some studies.

Presenter: Moving on to Clostridium Collagenase. What role does it play?

Dr. Tas: Clostridium Collagenase, an enzyme breaking down collagen in the plaque, has shown positive effects in reducing plaque size and improving curvature. It’s FDA-approved for use in certain patients with noncalcified plaque.

Presenter: Lastly, what’s the role of Platelet-Rich Plasma in Peyronie’s treatment?

Dr. Tas: Platelet-Rich Plasma, though in its early stages in urology, is used in Peyronie’s treatment. Autologous Platelet-Rich Plasma injections are considered a safe option, especially when combined with EWST and enzyme treatments, yielding successful results in specific cases with non-calcified plaque.

Presenter: Thank you, Dr. Tas, for sharing your insights. For those seeking more information, where can they reach you?

Dr. Tas: Our contact details are available on our website. I wish everyone a healthy life.